Synthes Reports Local Currency Sales Growth of 10.0% for Third Quarter 2009 and Maintains Double-Digit Sales Growth through First Nine Months 2009

Synthes (SWX: SYST.VX) today announced its Third Quarter and First Nine Months 2009 sales results with growth of 7.5% and 5.2%, respectively (10.0% and 10.3%, respectively, in local currency [LC]).

Third Quarter 2009

# Consolidated sales of US$ 868.3 million increased by US$ 60.6 million vs. prior year (PY)
# North America sales growth continued to accelerate in spite of ongoing economic challenges
# Asia Pacific maintained strong growth momentum due to solid performance in Japan and developing markets
# «Rest of World» growth slowed due to the absence of significant Middle Eastern tender orders, which favorably impacted previous year’s third quarter
# Synthes was awarded a permanent injunction and enhanced damages by a U.S. District Court in the ProDisc®-L patent case against Medtronic
# Synthes entered into a strategic agreement with Kensey Nash Corporation, allowing Synthes to market a unique porcine dermis-based extracellular matrix product

First Nine Months 2009

# Consolidated sales of US$ 2,504.3 million increased by US$ 123.1 million vs. PY (US$ 244.7 million in LC)
# North America’s growth was driven by new products across all product groups and superior customer service from the sales force despite a recessionary U.S. economy
# Europe and Asia Pacific achieved double-digit sales growth in all product groups

Michel Orsinger, President and CEO of Synthes, comments on the performance:
“We are pleased with our third quarter sales results, especially with North America returning to double-digit growth. This is a result of new product introductions and of our sales force providing high quality services to our customers.”

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button